Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.
Alessandro RizzoVeronica MollicaSara MerlerFranco MorelliGiulia SorgentoniMarco OderdaMatteo SantoniFrancesco MassariPublished in: Expert opinion on drug metabolism & toxicology (2022)
Clinicians should carefully consider these risks, especially taking into account that the use of PARPi in mCRPC patients is expected to rise in the near future.